Key Insights

Highlights

Success Rate

94% trial completion (above average)

Treatment Research

20 treatments under study, led by Atorvastatin

Published Results

201 trials with published results (24%)

Research Leaders

20 sponsors active, led by Organon and Co

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

5.1%

43 terminated out of 850 trials

Success Rate

94.0%

+7.4% vs benchmark

Late-Stage Pipeline

37%

311 trials in Phase 3/4

Results Transparency

30%

201 of 677 completed with results

Key Signals

201 with results94% success43 terminated

Data Visualizations

Phase Distribution

728Total
Not Applicable (226)
Early Phase 1 (6)
Phase 1 (67)
Phase 1/2 (9)
Phase 2 (102)
Phase 2/3 (7)
Phase 3 (197)
Phase 4 (114)

Trial Status

Completed677
Unknown69
Terminated43
Recruiting20
Not Yet Recruiting12
Active Not Recruiting12

Trial Success Rate

94.0%

Benchmark: 86.6%

Based on 677 completed trials

Clinical Trials (850)

Showing 20 of 20 trials
NCT00353782RecruitingPrimary

Causes and Natural History of Dyslipidemias

NCT04073797Not ApplicableCompletedPrimary

PET Imaging of Inflammation and Lipid Lowering Study

NCT07892092CompletedPrimary

Long-Term Cardiovascular Impact of ArmoLIPID Cholesterol Plus: An In Silico Study Using Digital Twins

NCT05362903CompletedPrimary

A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting

NCT07083206RecruitingPrimary

A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe

NCT06451770Phase 1RecruitingPrimary

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

NCT07821944Phase 3Recruiting

A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)

NCT00001154Completed

Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins

NCT07477704Phase 2Active Not RecruitingPrimary

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

NCT03206164Not ApplicableCompleted

HealthMatters@24/7 eLearning for People Supporting Adults With Intellectual and Developmental Disabilities

NCT05325034Not ApplicableRecruiting

Guideline Oriented Approach To Lipid Lowering In Asia-Pacific

NCT07852481Not ApplicableNot Yet RecruitingPrimary

Metabolic Effects of an Ophiocordyceps Sinensis- and CoQ10-Based Formulation in Mild-to-Moderate Hypercholesterolemia

NCT04579367Active Not RecruitingPrimary

Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

NCT07474649Phase 3Not Yet Recruiting

A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events

NCT05952856Phase 3CompletedPrimary

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

NCT07839936Phase 2Not Yet Recruiting

A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

NCT07803679Phase 4Not Yet Recruiting

A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma

NCT02694094Active Not RecruitingPrimary

Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy

NCT07382414Not ApplicableNot Yet Recruiting

Electronic Letters to Improve Patient Activation in IHD: The NUDGE-IHD Trial

NCT07789366Not ApplicableNot Yet RecruitingPrimary

Berberol P for Mild-to-Moderate Hypercholesterolaemia

Scroll to load more

Research Network

Common Treatments

  • Atorvastatin92
  • Ezetimibe91
  • Rosuvastatin50
  • Simvastatin45
  • Alirocumab41

Active Sponsors

  • Organon and Co85
  • Sanofi45
  • National Heart, Lung, and Blood Institute (NHLBI)43
  • Regeneron Pharmaceuticals, Inc.41
  • Merck Sharp & Dohme LLC39

Top Investigators

Related Conditions

  • Hypertension87
  • Cardiovascular Diseases54
  • Atherosclerosis41
  • Dyslipidemias33
  • Dyslipidemia32

Activity Timeline